Areas of Interest

Gastroenterology Partnerships 

Gastroenterology Partnership Opportunities 

Galen works with Almac Group in the development of gastroenterology products, combining specialist development expertise with Galen’s strengths in commercialisation, marketing, distribution and global licensing. Together, these capabilities support the journey from development to international markets, helping bring treatments to patients who need them.

Chronic conditions like inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation significantly affect patients’ quality of life and continue to strain global healthcare systems. 

One of the key challenges in managing chronic conditions is adherence to treatment. Studies suggest that only around 50% of patients with chronic illnesses in developed countries take their medicines as prescribed.². 

Poor adherence can be associated with worse clinical outcomes and increased healthcare utilisation. Even when new treatments are developed, they still face hurdles in securing approval and achieving widespread adoption.

That’s where Galen steps in. By supporting commercial strategy and regulatory execution, we help promising therapies in gastroenterology navigate the path from approval to adoption, helping them reach the patients who need them.

Galen brings more than just operational support; we offer focus, speed, and the kind of personalised collaboration that only a smaller, agile partner can provide. 

Regulatory Support

Accelerating approvals by navigating complex pathways with precision

Market Access Strategies

Building tailored launch plans that match patient and system needs

Distribution Networks

Leveraging well-established supply channels to ensure consistent availability

We work side-by-side with innovators to deliver flexible, responsive solutions that are focused on meeting patient needs, while maximising commercial potential. Our independence and scale allow us to adapt quickly, act decisively, and maintain focus on the end goal, getting therapies into the hands of those who need them most.

Galen is actively seeking late-stage or market-ready gastroenterology products to complement our growing portfolio of high-quality, patient-focused therapies. 

We are particularly interested in treatments that improve patient comfort, support long-term adherence, or reduce the burden of chronic gastrointestinal conditions. These may include:

  • Treatments for constipation, IBD, or IBS
  • Therapies that improve gut motility or reduce inflammation
  • Products that offer simplified dosing or enhanced tolerability 

We’re also open to opportunities beyond this list. Our model enables us to rapidly evaluate and onboard innovations across the gastroenterology spectrum, even those outside our current therapeutic focus.

If you’re looking for a partner who offers speed, flexibility, and commercial focus, Galen is ready to support your product’s journey to market. 

References 

  1. Wang, Y., Huang, Y., Chase, R.C., Antwi, S.O., Keaveny, A.P. and Pang, M. (2023) ‘Global burden of digestive diseases: a systematic analysis of the Global Burden of Diseases study, 1990 to 2019’, Gastroenterology, 165(3), pp.773–783.e15. Available at: https://www.gastrojournal.org/article/S0016-5085(23)00825-9/fulltext (Accessed: 12 October 2026).
  2. Brown, M.T. and Bussell, J.K. (2011) ‘Medication adherence: WHO cares?’, Mayo Clinic Proceedings, 86(4), pp.304–314. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3068890/ (Accessed: 12 October 2026).

Interested in Partnering with Us?

If you would like to explore how our expertise could add value to your product or for an initial discussion about partnering with us, get in touch today.

Contact Us

Aimee Lappin

Business Development Support Manager

Johnny McGaughey

Vice President of Business Development

Natasha Guy

Business Development Licensing Manager

If you would like to learn more about partnering with Galen, explore career opportunities, or speak with our teams, we invite you to get in touch and continue the conversation.